Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.42 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2578820 | 0.94 | RXFP1 (0.45) | CA12CA9CA1TAS2R14ALDH1A1 | |
| SCHEMBL7959979 | 0.90 | RORC (0.44) | TAS2R14CNR2MEN1KMT2ABACE1 | |
| SCHEMBL2576474 | 0.90 | RORC (0.44) | TAS2R14CNR2MEN1KMT2ABACE1 | |
| SCHEMBL7959974 | 0.90 | RORC (0.44) | TAS2R14CNR2MEN1KMT2ABACE1 | |
| SCHEMBL2582413 | 0.88 | SPPL2A (0.52) | TAS2R14RORC | |
| SCHEMBL2582931 | 0.83 | TAS2R14 (0.47) | TAS2R14CNR2MEN1KMT2ARORC | |
| SCHEMBL2578910 | 0.83 | TAS2R14 (0.47) | TAS2R14CNR2MEN1KMT2ABACE1 | |
| SCHEMBL2581281 | 0.82 | TAS2R14 (0.51) | TAS2R14BACE1 | |
| SCHEMBL6764842 | 0.82 | SPPL2A (0.53) | TAS2R14BACE1RORC | |
| SCHEMBL2578860 | 0.81 | MAPK1 (0.47) | RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | claimed |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-11-18 | — | — | US | claimed |
| US-20040044047-A1 | Alpha and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-03-04 | — | — | US | claimed |
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-10-09 | — | — | US | claimed |
| US-6455581-B1 | INHIBITORS OF HIV PROTEASE. | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | claimed |
| EP-0810209-B1 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | SEARLE & CO (US) | 2002-06-05 | — | — | EP | claimed |
| EP-0810209-A2 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | claimed |
| WO-1995006030-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | claimed |
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-7829564-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2009-01-22 | — | — | US | disclosed |
| US-7115618-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| US-6846954-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-11-18 | — | — | US | disclosed |
| EP-0810209-B1 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | SEARLE & CO (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6335460-B1 | TREATING RETROVIRAL INFECTIONS, INCLUDING HUMAN IMMUNODEFICIENCY VIRUS, AND AIDS | G.D. SEARLE & CO. | 2002-01-01 | — | — | US | disclosed |
| US-6172082-B1 | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | G. D. SEARLE & CO. | 2001-01-09 | — | — | US | disclosed |
| US-6060476-A | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0656887-B1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-10-28 | — | — | EP | disclosed |
| EP-0810209-A2 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | DNPEP, ASPH, PREP | CA12 1843/4885CA9 1906/4885CA1 525/4885 |
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | CA12 1603/4885CA9 2041/4885CA1 484/4885 |
| US-20040044047-A1 | Alpha and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, PREP, ANPEP | CA12 1649/4885CA9 2075/4885CA1 512/4885 |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | CA12 1603/4885CA9 2041/4885CA1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.